腹腔内生物材料治疗腹壁疝的长期性能评估
这项回顾性多中心病例回顾评估了混合复合补片GORE® SYNECOR腹腔内生物材料在腹壁疝修补中的长期安全性和器械性能。纳入459例患者(469个腹壁疝),平均随访32个月,补片相关复发率为0.9%,30天手术相关不良事件发生率为5.0%,结论认为在多数患者中取得了成功结局。
要点
- 混合复合补片用于腹壁疝修补,平均随访32个月确认复发率仅0.9%。
- 30天内手术相关不良事件发生率5.0%,12个月内手术部位感染或手术部位事件发生率3.8%。
核心结论
- 使用混合复合补片行腹壁疝修补在多数患者中取得成功的长期结局。
- 数据确认了在以VHWG2为主的人群中可接受的长期安全性和器械性能,复发率低。
研究设计与样本
- 回顾性、多中心、病例回顾研究。
- 纳入459例患者(469个腹壁疝),平均年龄58±15岁,平均随访32个月(范围14-53个月)。
主要发现
- 平均疝大小为18.9 cm²,57.3%为切口疝。
- 95.4%的患者采用腹腔镜或机器人入路,75.6%补片置于腹腔内,57.3%行桥接修补。
- 30天内手术相关不良事件发生率为5.0%,包括手术部位感染、手术部位事件、肠梗阻、再入院和再手术。
- 12个月内手术相关手术部位感染或手术部位事件发生率为3.8%,24个月内需手术干预的手术部位事件发生率为2.6%。
临床怎么用
- 对于腹壁疝修补,可考虑使用混合复合补片行腹腔内放置,尤其适用于VHWG2患者。
- 术后需关注手术部位感染和手术部位事件,尤其在合并糖尿病的患者中。
局限性
- 回顾性设计可能引入选择偏倚和信息偏倚。
- 研究人群异质性较大,涉及不同手术入路、补片固定方式和补片放置位置。
- 随访时间范围较宽(14-53个月),可能影响长期结局的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One-year device safety and clinical outcomes of ventral hernia repair with the GORE® SYNECOR Intraperitoneal Biomaterial, a hybrid composite mesh was evaluated. METHODS: This retrospective, multicenter, case review analyzed device/procedure endpoints and patient-reported outcomes in patients treated for hernia repair ≥ 1 year from study enrollment. RESULTS: Included were 459 patients (with 469 ventral hernias) with a mean age of 58 ± 15 years; 77.1% met Ventral Hernia Working Group 2 (VHWG2) classification. Mean hernia size was 18.9 cm2 and 57.3% of hernias were incisional. Laparoscopic or robotic approach was utilized in 95.4% of patients. Mesh location was intraperitoneal for 75.6% and bridging repair was performed in 57.3%. Procedure-related adverse events within 30-days occurred in 5.0% of patients and included surgical site infection (SSI), surgical site occurrence (SSO), ileus, readmission, and re-operation. Procedure-related SSI or SSO events were 3.8% through 12 months. SSO events requiring procedural intervention (SSOPI) were 2.6% through 24 months. Four patients (0.9%) had confirmed hernia recurrence through the study (the mean follow-up was 32-months, range 14-53 months). Subgroup comparisons were conducted for all type recurrence; only diabetes was found to be statistically significant (p = .0506). CONCLUSION: In this analysis, ventral hernia repair with hybrid, composite mesh results in successful outcomes in most patients. This study represents a heterogeneous patient population undergoing repair using various approaches, mesh fixation, and mesh placement locations. These data appear to confirm long-term acceptable safety and device performance with a low rate of recurrence in a predominantly VHWG2 population.
引用
- Linn JG, Mallico EJ, Doerhoff CR, et al. Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias. Surg Endosc. 2022. PMID: 36550313. doi:10.1007/s00464-022-09803-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。